Infant Pulmonary Mechanics: High Flow Nasal Cannula Versus Nasal CPAP

Phase 1

Withdrawn

• Conditions: Respiratory Distress; Lung Injury
• Interventions: Device: Nasal Continuous Positive Airway Pressure; Device: Heated Humidified High Flow Nasal Cannula

• Registration Number: NCT01939067
• Lead Sponsor: Children's Hospital of Philadelphia

Brief Summary

This study is designed to evaluate the effect of heated humidified high flow nasal cannula (HHHFNC) as compared to noninvasive nasal continuous positive airway pressure (NCPAP) on lung function as a measure of lung injury in preterm infants born at 28 to 37 weeks gestation requiring continuing respiratory support.

Detailed Description

Respiratory distress and the need for respiratory support continues to be a common problem for preterm infants. Presence of the breathing tube and duration of respirator provided breaths have been shown to be associated with increased risk for secondary lung injury and subsequent development of chronic lung disease of prematurity. Early application of noninvasive nasal continuous positive airway pressure (NCPAP) has been shown to be an effective, non-invasive, mode of respiratory support in preterm infants and to be associated with a lower incidence of chronic lung disease. A recently published large randomized multicenter study concluded that, among infants born at 28 weeks and longer gestation, heated humidified high flow nasal cannula (HHHFNC) had similar clinical efficacy and safety as compared to NCPAP. Both NCPAP and HHHFNC are currently used to assist infants with breathing problems.

This study is designed to evaluate the effect of HHHFNC as compared to NCPAP on lung function as a measure of lung injury in preterm infants born at 28 to 37 weeks gestation requiring continuing respiratory support. In this study, infants will remain on the assigned treatment of either NCPAP or HHHFNC until they require more support as provided by a respirator or until a treatment cross-over from NCPAP to HHHFNC, or the reverse, as decided by their attending physician. The infant's respiratory support will be managed according to his/her attending doctor as per accepted standards of care. A pulmonary function test will be performed twice weekly on each enrolled infant while receiving either NCPAP or HHHFNC support, followed-up by once weekly lung function measurements post respiratory support while infants are breathing only room air until discharge.

Study Timeline

• Study First Submitted: 2013-08-30
• Study First Submitted QC: 2013-09-09
• Study First Posted: 2013-09-11
• Study Start: 2014-03
• Primary Completion: 2014-03
• Study Completion: 2014-03
• Status Verified: 2015-09
• Last Update Submitted: 2015-09-14
• Last Update Posted: 2015-09-15

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Birth weight greater than or equal to 1000 grams.

2. Gestational age at birth between 28 weeks and 37 weeks (28 0/7 to 37 6/7 weeks inclusive).

3. Candidate for non-invasive respiratory support as a result of:

   1. An intention to manage the infant with non-invasive (no endotracheal tube) respiratory support.
   2. An intention to extubate an infant being managed with intubated respiratory support to non-invasive respiratory support.

4. Subjects must have a guardian or acceptable surrogate capable of giving consent on his/her behalf.

Exclusion Criteria

1. Birth weight less than 1000 grams.
2. Estimated gestation at birth less than 28 weeks or greater than 37 6/7 weeks.
3. Active air leak syndrome.
4. Subjects will not be eligible if they are not considered viable.
5. Infants with abnormalities of the upper and lower airways
6. Infants with significant abdominal or respiratory malformations .

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
NCPAP	Nasal Continuous Positive Airway Pressure	Treatment of respiratory distress by nasal continuous positive airway pressure (NCPAP). Escalation of the ventilatory support per protocol and the attending physician.
HHHFNC	Heated Humidified High Flow Nasal Cannula	Treatment of respiratory distress by Heated Humidified High Flow Nasal Cannula (HHHFNC). Escalation of the ventilatory support per protocol and the attending physician.

Primary Outcome Measures

Name	Time	Method
Pulmonary mechanics and chest wall asynchrony measures.	2 years	Pulmonary mechanics measures consisting of dynamic lung compliance, airway resistance, and work of breathing and chest wall asynchrony measures consisting of thoracoabdominal asynchrony, labored breathing index and rib cage to abdominal phase relation during the total breath are measured in preterm infants treated with HHHFNC and compared to the same measurements in preterm infants treated with NCPAP.

Secondary Outcome Measures

Name	Time	Method
Duration of respiratory support or oxygen use up to the time of discharge from the NICU.	2 years	The total number of days while infants are on any type of respiratory support or oxygen use prior to discharge in preterm infants treated with HHHFNC compared to NCPAP during their hospital stay.
The incidence of potential adverse outcomes associated with HHHFNC or NCPAP.	2 years	The number and percentage of infants in each group with adverse effects such as facial and upper airways injury associated with the use of HHHFNC or NCPAP.
Time needed to establish full enteral feeds	2 years	The total number of days needed to establish full enteral feeds in preterm infants treated with HHHFNC as compared to preterm infants treated with NCPAP.

Trial Locations

Locations (1)

Pennsylvania Hospital; 🇺🇸 Philadelphia, Pennsylvania, United States